Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q3 2021 · 10-Q
Revenue$108.00K$108.00K−81.2% vs Q3 2020 Net Income-$2.32M-$2.32MN/M vs Q3 2020 EPS Diluted-$0.06-$0.06N/M vs Q3 2020 Gross Profit$14,000−53.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,845,000N/M Free Cash Flowderived-$1,997,000N/M Margins · derivedGross margin13.0%+7.7 pt vs Q3 2020
Operating margin-2153.7%−1860.9 pt vs Q3 2020
Net margin-2150.9%−1871.2 pt vs Q3 2020
ended Dec 31, 2020 · filed Feb 16, 2021 · 47 d after period end